# Rituximab in Combination With Outpatient Therapy for CD20+ Lymphoma

> **NCT00280878** · PHASE2 · COMPLETED · sponsor: **Bayside Health** · enrollment: 12 (estimated)

## Conditions studied

- Non-Hodgkin's Lymphoma (CD20+)

## Interventions

- **DRUG:** gemcitabine
- **DRUG:** vinorelbine
- **DRUG:** ifosfamide
- **DRUG:** rituximab

## Key facts

- **NCT ID:** NCT00280878
- **Lead sponsor:** Bayside Health
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-01
- **Primary completion:** —
- **Final completion:** 2007-09
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2016-01-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00280878

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00280878, "Rituximab in Combination With Outpatient Therapy for CD20+ Lymphoma". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT00280878. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*